Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2025 | 03-2025 | 09-2024 | 03-2024 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,346 | 4,229 | 7,286 | 3,589 | 5,108 |
| Receivables | 176 | 31 | 26 | 218 | 183 |
| Inventories | 54 | 95 | 125 | 60 | 25 |
| Other current assets | 0 | 540 | 596 | 513 | 655 |
| TOTAL | $4,149 | $4,894 | $8,033 | $4,380 | $5,971 |
| Non-Current Assets | |||||
| PPE Net | 1,275 | 1,544 | 1,230 | 952 | 523 |
| Other Non-Current Assets | 290 | 0 | 0 | 0 | 375 |
| TOTAL | $1,566 | $1,544 | $1,230 | $952 | $898 |
| Total Assets | $5,715 | $6,427 | $9,443 | $5,484 | $7,025 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 196 | 33 | 223 | 0 | N/A |
| Accounts payable and accrued liabilities | 104 | 588 | 423 | 121 | 737 |
| TOTAL | $366 | $673 | $694 | $169 | $787 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 276 | 0 | 0 | 0 | 0 |
| TOTAL | $276 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $642 | $965 | $1,026 | $345 | $919 |
| Shareholders' Equity | |||||
| Common Shares | 7 | 4 | 4 | 3 | 2 |
| Retained earnings | -26,928 | -24,589 | -21,284 | -18,528 | -14,802 |
| Other shareholders' equity | 31,995 | 30,047 | 29,697 | 23,664 | 20,906 |
| TOTAL | $5,074 | $5,462 | $8,417 | $5,139 | $6,106 |
| Total Liabilities And Equity | $5,715 | $6,427 | $9,443 | $5,484 | $7,025 |